Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD6001 plus Toripalimab in Advanced Melanoma
NCT05723432Phase 2Recruiting
- Sponsor
- Shanghai Kanda Biotechnology
- Start
- Mar 2023
- Primary completion
- Dec 2024
- Modality
- IgG Antibodies, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KD6001 in melanoma, sponsored by Shanghai Kanda Biotechnology. Primary endpoints: Dose Limiting Toxicities at 21 days, Adverse Events, Serious Adverse Events, and Immune-related Adverse Events at 2 years and 2 more. Started Mar 2023; status: recruiting.
02
Drugs
KD6001
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05723432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05723432.